BY MARKETWIRE
-
Novo Nordisk’s Head of US to step down in the New Year and become an advisor – Head of Strategy will take over
Rather, he will certainly concentrate a lot more on his exclusive life.
-
Ambu makes USD 49m impairment in gastroenterology
The factor is the trouble of passing through the gastroenterology endoscopy market.
-
Strong retail business limits Q3 disappointment for Demant
While other business areas disappointed, the retail business performed surprisingly well in the recent quarter.
-
Olympus impresses with second quarter profits
Although earnings dissatisfies at Olympus, the Japanese endoscope maker still gains greater than experts anticipated.
-
Genmab on key decision: Partner must decide on potential Darzalex replacement by Q1
The choice will certainly be based upon information from a huge comparitive research study in between the possible follower Hexabody-38 and Darzalex Faspro.
-
GN’s earnings outperform prognosis despite revenue pressured by negative organic growth
The company downgrades full-year growth expectations.
-
Zealand Pharma’s pre-tax loss lower than expected despite revenue decline
Zealand Pharma generated income of DKK 4.4 million in July, August and September.
-
Genmab to release 20 abstracts at hematology conference
New clinical results for the treatment of non-hodgkin’s lymphoma will be presented at the American Society of Hematology (ASH) conference in December.
-
Demant CEO: We aren’t shying away from tough market competition
Along with challenging competitors, a weak market and a challenging contrast basis contributed in Demant’s weak than anticipated Q3 outcome.
-
Novo Nordisk at risk of minor miss ahead of key December announcement, analysts suggest
The Danish pharmaceutical firm’s share cost has actually shed 25% worth given that it coming to a head in the summertime.
